Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Specific investigations: other studies

Currently viewing:

Administrative data

Link to relevant study record(s)

Referenceopen allclose all

Endpoint:
endocrine system modulation
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment
Principles of method if other than guideline:
The ERE-CALUX bioassay was used to determine the estrogenic activity of the compounds. This is a bioanalytical tool that uses a human breast cancer cell line, which is stably transfected with an ER responsive luciferase reporter gene (VM7Luc4E2). 17β-Estradiol (E2) was used as a reference standard.
GLP compliance:
not specified
Type of method:
in vitro
Conclusions:
HEMA showed no estrogenic activity under the conditions of this assay.
Endpoint:
endocrine system modulation
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Screening test.
Details on study design:
Type: other: estrogenic activity


2-HEMA did not show any estrogenic activity at concentrations between  10E-7 and 10E-3 M.

Description of key information

In severals screening tests 2-HEMA did not show any estrogenic activity at concentrations between  10E-7 and 10E-3 M.

Additional information